Overall Survival Clinical Trial
Official title:
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma: a Prospective, Randomized, Controlled, Multicenter Clinical Study
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years. Progression-free survival (PFS)was defined as the duration from randomization to the first evidence of disease progression or death from any cause. Overall survival (OS) was defined as the duration from the randomization to death from any cause. The Kaplan-Meier method was employed to plot the survival curves, with the log-rank test to assess the differences. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04025840 -
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
|
Phase 4 | |
| Completed |
NCT04111926 -
Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery
|
Phase 4 | |
| Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03910140 -
TILA-TACE in Treatment of Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT03923400 -
Jejunoileal vs Gastric GIST in the Era of Imatinib.
|
||
| Withdrawn |
NCT02201381 -
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
|
Phase 3 | |
| Recruiting |
NCT05392257 -
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
|
Phase 2 | |
| Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
| Recruiting |
NCT05310357 -
Chromosomal Instability in Ovarian Cancer
|
||
| Recruiting |
NCT05310370 -
HRD and Resistance to PAPPi in EOC Patients
|
||
| Active, not recruiting |
NCT04245644 -
Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
|
||
| Recruiting |
NCT04245410 -
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
|
||
| Completed |
NCT02980185 -
Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT03967457 -
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
|
||
| Recruiting |
NCT04050787 -
Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer
|
N/A | |
| Recruiting |
NCT03892577 -
Real-world Study for Patients With Advanced Hepatobiliary Tumors
|
||
| Completed |
NCT03726021 -
Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02942238 -
Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)
|
N/A | |
| Not yet recruiting |
NCT01236989 -
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC
|
N/A |